Kornimate/medical-research-clean huggingface dataset:
pilot study of elk-003 eye drops for treating ocular manifestations of epidermolysis bullosa

Conditions: Junctional Epidermolysis Bullosa; Epidermolysis Bullosa (EB); Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa

Summary: this study consists of two phases: an observational phase to evaluate the natural history of ocular manifestations in subjects with dystrophic and junctional epidermolysis bullosa, followed by a treatment phase to assess the effects of elk-003 eye drops. each subject will serve as their own control by comparing ocular manifestations documented during the observational phase to those recorded during the treatment phase.

during this study, subjects will undergo evaluations at three scheduled clinic visits: at enrollment (baseline, time 0), at 4 months, and at the conclusion of the treatment phase (6 months post-treatment initiation). assessments will include oct imaging, slit lamp examination with photographs, keratograph analysis, visual acuity testing, osmolarity testing, inflammadry, spk scoring, schirmer test, and opacity scoring. weekly questionnaires will be completed by subjects to assess symptoms, track corneal abrasions, and evaluate quality of life throughout the study. if subjects experience symptoms indicative of corneal abrasions, a healthcare provider will conduct a home visit to document the event, using fluorescein staining to confirm and record the corneal abrasion. corneal abrasion symptoms, frequency, duration, and healing outcomes will be monitored.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of recessive dystrophic and junctional epidermolysis bullosa * frequent history of corneal abrasions (one or more abrasions every 3 months) * age: older than 2 years at the time of joining the clinical trial * patients and/or parent/legal guardian has given written informed consent in writing exclusion criteria: * acute eye infection at time of enrollment * patients with severe vision loss (\<20/200) or severe corneal opacification. * contact lens wear or nocturnal eye ointment * hypersensitivity to fluorescein (ocular stain used in slit lamp study) * history of alcohol abuse or drug addiction * patient who reports difficulty to attend the 4 in-person controls * patients who are suffering from cancer * patients with any medical condition or situation which in the opinion of the investigators could put the patient at risk, or could interfere with the patient's participation in the study * pregnant or breastfeeding women (a pregnancy test will be performed using a urine sample for female patients who have had menarche).

Keywords: ocular manifestations of eb corneal abrasion elk-003 debra chile eliksa therapeutics epidermolysis bullosa
a pilot feasibility study comparing smartphone home-based rehabilitation program against the usual hospital and outpatient physiotherapy care on clinical and cost effectiveness for total knee replacement patients

Conditions: Knee Arthropathy

Summary: knee osteoarthritis (oa) is a common, chronic, and costly condition whilst total knee replacement (tkr) is a common orthopaedic surgical intervention. in singapore, after tkr surgery, nearly all patients who are home discharged are referred to hospital-based outpatient rehabilitation. although outpatient rehabilitation attendance is associated with better functional outcomes, access to rehabilitation care is limited as outpatient rehabilitation is costly and inconvenient for patients and their caregivers, resulting in suboptimal adherence. a smartphone home-based rehabilitation program provides the best access to rehabilitation care and is a potential alternative for the majority of patients who do not require intensive "hands-on" rehabilitation therapy. the primary aim of this randomized controlled trial is to compare patient functional outcomes and cost-effectiveness of this innovative smartphone home-based exercise program versus that of currently standard, hospital-based outpatient rehabilitation program among post tkr patients in the department of physiotherapy, singapore general hospital.

thirty patients undergoing tkr for knee oa will be randomly assigned to receive either smartphone home-based rehabilitation program or hospital-based rehabilitation program following surgery for a rehabilitation period of 24 weeks. the primary patient functional outcome will be fast gait speed. outcomes will be assessed preoperatively, at 12-week and 24-week after surgery by an assessor masked to group allocation. if shown to be non-inferior to the standard outpatient rehabilitation, smartphone home-based exercise program can be recommended as a cost effective treatment option for patients with tkr.

Eligibility criteria:
inclusion criteria: 1. primary unilateral total knee replacement 2. age \>= 45 years 3. under the enhanced recovery after surgery (eras) programme (discharge on post-operative day 0/1) 4. able to ambulate independently without an assistive device 5. willingness to be randomized to either smartphone home-based rehabilitation program or outpatient rehabilitation 6. ability to provide informed consent 7. able to operate phone application and use online platform 8. able to read and understand english or mandarin exclusion criteria: 1. rheumatoid arthritis and other systemic arthritis 2. significant back or other non-knee pain 3. a previous history of stroke and other major neurological conditions 4. an intention to transfer to step-down care facilities post-operatively

Keywords: knee arthroplasty; orthopedic procedures; outcome assessments; self- help devices; technology; knee: treatment outcome
the effectiveness of interactive nursing education program through health belief model based and informative technology-assisted on atrial fibrillation patients receiving oral anticoagulant

Conditions: Atrial Fibrillation

Summary: this study examined patients on taking oral anticoagulants (oacs) are often prescribed for atrial fibrillation (afib) to determine the effectiveness of a multiple interactive health education program, which was developed based on the health belief model (hbm) and incorporated information technologies.

a randomized controlled study was conducted on the cardiology outpatients. the patients were recruited through purposive sampling. the participants had been diagnosed with afib and were receiving oacs. the participants were divided according to the blocks of clinic hours and assigned randomly to the experimental group or control group. the control variables involved demographic characteristics and medical history. the dependent variables and corresponding research instruments were medication knowledge and health beliefs, medication satisfaction and quality of life (qol). other than the medication knowledge questionnaire, which was assessed monthly, all the measurement instruments were applied twice: first in a pretest, and again in a posttest administered at the third month. the interventions administered to the experimental group were one-on-one instruction and hbm-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. the participants in the control group only received brochure and medication cards.

Eligibility criteria:
inclusion criteria: * diagnosis of atrial fibration by a physician and taking oral anticoagulant as treatment * 20years old or older * clear consciousness for communication * willingness to participate in research. exclusion criteria: * can not communicate clearly * without willingness to participate in research

Keywords: health education program health belief model informative technology anticoagulants atrial fibrillation randomized controlled study
comparison of the oxymask and oxy2mask on supplemental oxygen delivery

Conditions: Hypoxia

Summary: the purpose of this study is to determine if the performance of a newly released oxygen mask is the same, better, or worse than previous mask version. we will measure the flow rate necessary to maintain the same oxygen saturation in adult patients using each mask.

southmedic, inc. has received approval to distribute a newly designed oxygen mask. the current design has been studied and the fio2 delivered reported to be inconsistent. the purpose of this study is to determine if the performance is the same, better, or worse than current mask. we can evaluate performance by determining liter flow required to maintain oxygen saturations that are within limits described in nm cdh oxygen protocol. we will measure the flow rate necessary to maintain the same saturation in adult patients using both the oxymask and oxy2mask. the oxymask has a flow device inside the mask that has been revised since implementation. the mask itself is otherwise unchanged. we intend to determine if the same amount of flow results in the same outcome. this study will include adult patients that require supplemental oxygen and we do not believe the patients will report a difference between each mask. the only variance in care is mask version used, the oxygen protocol will remain the same.

Eligibility criteria:
inclusion criteria: * participants have oxygen device and are being titrated per nm cdh oxygen protocol (maintained between 90%-96%; or 88% - 92% if co2 retainer) * participants to have period of stability; 2 hours at same liter flow on open design mask, 5-15 lpm 02. * all adult patients (\> 18 years old) in med surge units (bed tower) * post-op patients requiring oxygen on post-op day 2. * patients currently on \>5 lpm via nasal cannula, clinician can recommend the change to oxymask. if remains on \>5 lpm via oxymask, patient can be included. * oxygen protocol will be followed per standards of care. exclusion criteria: * patients receiving home oxygen therapy who do not require additional oxygen during hospital stay. * patients with a history of bleomycin therapy. * patients with a history of paraquat poisoning * patients that are pregnant
the effect of fluid management by pleth variability index on acute kidney injury in obese patients

Conditions: Laparoscopic Colorectal Surgery; Acute Kidney Injury

Summary: this study was to find out whether laparoscopic colorectal surgery is detrimental to the kidneys via pvi monitoring. to detect the kidney injury, so-called kidney troponin ngal ,which gives earlier information than creatin in renal ischemic injury, was used.

our object in this study was to find out whether laparoscopic colorectal surgery is detrimental to the kidneys via pvi monitoring. to detect the kidney injury, so-called kidney troponin ngal ,which gives earlier information than creatine in renal ischemic injury, was used. patients undergoing elective laparoscopic colorectal surgery, 18 to 75 years old, planned surgery duration longer than 2 hours, were included in this study. patients were divided into 2 groups with respect to their fluid resuscitation, group 1: goal directed fluid therapy via pvi monitoring group 2: conventional fluid resuscitation. blood samples were drawn from both groups for ngal measurement before co2 insufflation (t0), and at 6th(t1) and 12th(t2) hours after co2 insufflation. at the end of the surgery, sugammadex was given to all patients for reversal of muscular blockade.

Eligibility criteria:
inclusion criteria: * laparoscopic surgery * obese patient exclusion criteria: * patient refusal * major comorbidity * renal failure * diabetes mellitus

Keywords: ngal pvi
corticosteroid intralesional injection as an alternative treatment in oral pyogenic granuloma in the esthetic zone.

Conditions: Oral Pyogenic Granuloma

Summary: gingival pyogenic granuloma in the esthetic zone represents an esthetic problem. while surgical treatment may not give the premium esthetic demands, corticosteroid may acheive this balance.

in our practice, the investigators have found the use of topical steroids effectively induced regression of pgs. this protocol has been suggested by published case reports supported by the anti-inflammatory actions corticosteroid. this is a particularly valuable approach for patients who have pg in the esthetic zone allowing the surgeon to keep maximum amount of periodontal tissues.

Eligibility criteria:
inclusion criteria: * patients with oral pyogenic granuloma at the esthetic zone exclusion criteria: * patients who were not compliant to oral hygiene instructions and can not be motivated
reprieve system pilot study

Conditions: Acute Decompensated Heart Failure

Summary: the objective of the study is to evaluate the use of the reprieve system to decongest subjects with acute decompensated heart failure.


Eligibility criteria:
inclusion criteria: 1. hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema/swelling) and 1 sign (peripheral edema, ascites, jugular venous distension, pulmonary vascular congestion on chest radiography) 2. ≥10 lb. (4.5 kg) above dry weight either by historical weights or as estimated by health care provider. 3. patients ≥ 18 years of age able to provide informed consent and comply with study procedures. exclusion criteria: 1. inability to place foley catheter or iv catheter or other urologic issues that would predispose the patient to a high rate of urogenital trauma or infection with catheter placement. 2. hemodynamic instability as defined by any of the following: systolic blood pressure \<90 mmhg, use of vasopressors, use of iv inotropes to treat hypotension (systolic blood pressure \<90 mm hg) or suspected/confirmed low cardiac output/shock, mechanical circulatory support, uncontrolled arrhythmias, active severe bleeding, or confirmed or suspected cardiogenic shock. note: in the absence of the above conditions, use of inotropes to augment diuresis is permitted. 3. dyspnea due primarily to non-cardiac causes (e.g., severe chronic obstructive pulmonary disease or pneumonia). 4. acute infection with evidence of systemic involvement (e.g., clinically suspected infection with fever or elevated serum white blood cell count). 5. estimated glomerular filtration rate (egfr) \< 20 ml/min/1.73m2 calculated using the mdrd equation or current use of renal replacement therapy (rrt). 6. significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, known severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment (within previous week), or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated. 7. inability to follow instructions or comply with follow-up procedures. 8. other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures. 9. severe baseline electrolyte abnormalities (e.g., serum potassium \<3.0 meq/l or magnesium \<1.3 meq/l). note: these are based on baseline/screening labs. subjects whose electrolyte levels are repleted cannot be reassessed for inclusion in the trial. 10. serum sodium \<135 mmol/l or history of severe hyponatremia 11. poorly controlled diabetes 12. enrollment in another interventional trial during the index hospitalization 13. life expectancy less than 3 months 14. women who are pregnant or intend to become pregnant.
t790m mutation on ctdna in patients with nsclc after egfr-tki failure

Conditions: Non-small Cell Lung Cancer Stage III; Non-Small-Cell Lung Cancer Metastatic

Summary: the purpose of this study is to compare the frequency and abundance of t790m mutation among the different clinical modes of egfr-tki failure.

an observational, non-interventional, multi-central study of comparison of the frequency and abundance of t790m mutation using both amplification refractory mutation system (arms) and digital droplet pcr (ddpcr) methods among the different clinical modes of non-small cell lung cancer (nsclc) patients with epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki) failure

Eligibility criteria:
inclusion criteria: * histologically confirmed stage iiib/iv nsclc. * investigator confirmed progression according recist 1.1 during egfr-tki treatment within 28 days of the enrollment * activating mutation (g719a/c/s; exon 19 insertion/deletion; l858r; l861q) in the egfr gene or have had at least partial response with egfr tki lasting ≥ 6 months * patient must be able to comply with the protocol exclusion criteria: * response evaluation criteria in solid tumors (recist) 1.1 defined disease progression for more than 28 days while on previous egfr-tki treatment. * patient has been treated with any investigational agent for any indication within 4 weeks of study treatment. * histologically confirmed small cell lung cancer or other metastatic tumors * patient with no histologic or cytological diagnosis.

Keywords: non-small cell lung cancer circulating tumor dna t790m amplification refractory mutation system digital droplet pcr
implementation of refocus training program in mental health services

Conditions: Mental Disorders

Summary: training of mental health service teams in the orientation of care towards recovery through a 3-day training course: refocus. this training aims to orient care towards recovery. following this training, evaluation of the effectiveness of the implementation of refocus training in mental health services.

the primary hypothesis is that the implementation of refocus will facilitate the 1-year recovery of patients managed by trained professionals. the secondary hypotheses are that the implementation of refocus will facilitate improved orientation of practices towards recovery; reduced costs associated with the use of mental health services; improved perceived stigma, self-stigma, stigma-related stress, well-being, perceived coercion, and general functioning among those involved.

Eligibility criteria:
inclusion criteria: * age from 15 to 65 years old. * diagnosis of schizophrenia, schizoaffective disorder, schizotypal disorder and schizophreniform disorder or bipolar disorder, borderline personality disorder, disabling anxiety or depressive disorder (dsm-v criteria; apa, 2013). * patients cared for by the team or unit benefiting from refocus training * french mother tongue. * patient affiliated or entitled to a social security scheme * patient having received information about the study and having confirmed their participation in the study by signing the consent form * for minors (\< 18 years), information given to holders of parental authority and signature of consent. * for patients under curatorship, form signed by the patient and information given to the curator exclusion criteria: * age less than 15 years old * patients under guardianship * presence of an associated intellectual disability * neurological disorders of vascular, infectious or neurodegenerative origin. * taking somatic drugs with a cerebral or psychic impact (eg corticosteroids).
scleral fixation of bunnylens with goretex suture- initial results

Conditions: Aphakia, Acquired

Summary: this study evaluates the visual acuity and refraction of patients post 4-point scleral fixation of bunnylens (intra ocular lens- iol) with goretex sutures. all patients underwent secondary iol implantation or iol exchange during 2014-2017.

4 point scleral fixation of pc- iol (posterior chamber-pc) bunnylens with gore-tex sutures is a surgical technique for implanting iol in patients with capsular support absence, due to trauma, abnormal anterior chamber, iol dislocation, or ciliary zonule defect. the 4 point fixation enables to align the pc- iol with minimal vertical and horizontal deviation;the gore-tex sutures maintain stable scleral fixation with no suture erosion or breakage.

Eligibility criteria:
inclusion criteria: * patients that underwent secondary cataract surgery or iol replacement and bunnylens fixation with gore-tex sutures. exclusion criteria: * lack of cooperation, death, severe physical or mental illness, patient's request to withdraw of the clinical trial.
exploring clinical characteristics of liver disease patients based on digestive metabolic exhaled air

Conditions: Cirrhosis; Microbiota; Breath Tests

Summary: cirrhosis is a common digestive system disease and represents the final stage of the progression of various chronic liver diseases. during cirrhosis, the intestinal microenvironment is affected due to liver damage and increased portal venous pressure. displacement of gut microbiota is closely related to the occurrence and development of cirrhosis. disruption of the gut microbiota is associated with changes in the levels of nitric oxide (no), hydrogen (h₂), methane (ch₄), and hydrogen sulfide (h₂s). breath testing is an emerging method for assessing gut microbiota. this project aims to investigate the characteristics and prognosis of patients with chronic liver disease by detecting exhaled breath markers such as nitric oxide (no), hydrogen (h₂), methane (ch₄), and hydrogen sulfide (h₂s), in conjunction with results from serological tests, gut microbiota analysis, and radiomics. the goal is to identify new diagnostic biomarkers and therapeutic targets, to recognize high-risk patients at an early stage, and to improve patient survival rates and quality of life.


Eligibility criteria:
inclusion criteria: ① patients diagnosed with chronic liver disease or cirrhosis through liver biopsy pathology or clinical laboratory and imaging examinations; ② undergo molecular breath testing within one week of admission. exclusion criteria: * patients who have received antibiotic treatment within one month; ② patients with severe pulmonary diseases, such as chronic obstructive pulmonary disease (copd), asthma, or lung malignancies that have not been clinically cured; ③ patients who are unable to successfully complete the molecular breath test.
interventional radiology for the treatment of symptomatic portal hypertension in patients with cavernous transformation of portal vein

Conditions: Portal Vein, Cavernous Transformation Of; Hypertension, Portal

Summary: to evaluate the values of portosystemic shunt and other interventional radiology approaches for treatment of symptomatic portal hypertension in patients with cavernous transformation of portal vein.


Eligibility criteria:
inclusion criteria: * all patients with portal hypertention who have enough image information to confirm cavernous transformation of portal vein. exclusion criteria: * patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Keywords: portal vein, cavernous transformation of hypertension, portal radiology, interventional portalsystemic shunt